Jean-Jacques Kiladjian

List of Publications by Year
in descending order

102 papers	9,468 citations	87723 38 h-index	38300 95 g-index
102 all docs	102 docs citations	102 times ranked	5395 citing authors

#	Article	IF	Citations
1	JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis. New England Journal of Medicine, 2012, 366, 787-798.	13.9	1,543
2	Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet. Journal of Clinical Oncology, 2011, 29, 761-770.	0.8	724
3	Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood, 2008, 112, 3065-3072.	0.6	511
4	Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia, 2018, 32, 1057-1069.	3.3	415
5	Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood, 2013, 122, 4047-4053.	0.6	383
6	Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs. Journal of Clinical Oncology, 2012, 30, 4098-4103.	0.8	344
7	The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases. Blood, 2008, 111, 4922-4929.	0.6	319
8	Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis. Blood, 2012, 120, 4921-4928.	0.6	303
9	Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study. Lancet Haematology,the, 2017, 4, e317-e324.	2.2	243
10	SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitorâ€“NaÃ¯ve Patients With Myelofibrosis. Journal of Clinical Oncology, 2017, 35, 3844-3850.	0.8	243
11	High molecular response rate of polycythemia vera patients treated with pegylated interferon Â-2a. Blood, 2006, 108, 2037-2040.	0.6	240
12	Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. Blood, 2009, 113, 4829-4833.	0.6	229
13	Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial. Lancet Haematology,the, 2017, 4, e225-e236.	2.2	224
14	Treatment of Polycythemia Vera With Hydroxyurea and Pipobroman: Final Results of a Randomized Trial Initiated in 1980. Journal of Clinical Oncology, 2011, 29, 3907-3913.	0.8	223
15	Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project. Blood, 2013, 121, 4778-4781.	0.6	219
16	Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial. Lancet Haematology,the, 2018, 5, e73-e81.	2.2	211
17	Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses. Journal of Hematology and Oncology, 2017, 10, 156.	6.9	210
18	A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis. Haematologica, 2015, 100, 1139-1145.	1.7	203

#	Article	IF	Citations
19	Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 5 Haematology,the, 2020, 7, e196-e208.	2.2	199
20	Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations. Blood, 2011, 117, 2813-2816.	0.6	190
21	The renaissance of interferon therapy for the treatment of myeloid malignancies. Blood, 2011, 117, 4706-4715.	0.6	176
22	Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial. Haematologica, 2016, 101, 821-829.	1.7	140
23	Clinical and molecular response to interferon-Î± therapy in essential thrombocythemia patients with CALR mutations. Blood, 2015, 126, 2585-2591.	0.6	127
24	Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis. Leukemia, 2021, 35, 1-17.	3.3	116
25	Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis. Expert Review of Hematology, 2013, 6, 49-58.	1.0	96
26	Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the <scp>JAKARTA2</scp> study using stringent criteria for ruxolitinib failure. American Journal of Hematology, 2020, 95, 594-603.	2.0	96
27	Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study. Lancet Haematology,the, 2020, 7, e226-e237.	2.2	93
28	Luspatercept for the treatment of anemia in myelodysplastic syndromes and primary myelofibrosis. Blood, 2019, 133, 790-794.	0.6	75
29	Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study. Annals of Hematology, 2017, 96, 1113-1120.	0.8	68
30	Efficacy and safety of pegylatedâ€interferon Î±â€2a in myelofibrosis: a study by the <scp>FIM</scp> and <scp>GEM</scp> French cooperative groups. British Journal of Haematology, 2013, 162, 783-791.	1.2	67
31	Interferon Alfa Therapy in CALR-Mutated Essential Thrombocythemia. New England Journal of Medicine, 2014, 371, 188-189.	13.9	67
32	PEGâ€IFNâ€Î±â€2a therapy in patients with myelofibrosis. British Journal of Haematology, 2009, 146, 223-225.	1.2	64
33	Thromboembolic events in polycythemia vera. Annals of Hematology, 2019, 98, 1071-1082.	0.8	63
34	Randomized, Single-Blind, Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or Refractory Myelofibrosis. Journal of Clinical Oncology, 2021, 39, 2881-2892.	0.8	59
35	Symptomatic Profiles of Patients With Polycythemia Vera: Implications of Inadequately Controlled Disease. Journal of Clinical Oncology, 2016, 34, 151-159.	0.8	56
36	Selective testing for calreticulin gene mutations in patients with splanchnic vein thrombosis: A prospective cohort study. Journal of Hepatology, 2017, 67, 501-507.	1.8	50

#	Article	IF	Citations
37	Benefits and pitfalls of pegylated interferon-Î±2a therapy in patients with myeloproliferative neoplasm-associated myelofibrosis: a French Intergroup of Myeloproliferative neoplasms (FIM) study. Haematologica, 2018, 103, 438-446.	1.7	50
38	Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations. Lancet Haematology,the, 2022, 9, e301-e311.	2.2	46
39	A randomized phase 3 trial of interferon-Î± vs hydroxyurea in polycythemia vera and essential thrombocythemia. Blood, 2022, 139, 2931-2941.	0.6	45
40	A First-in-Human Phase I Study of INVAC-1, an Optimized Human Telomerase DNA Vaccine in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2020, 26, 588-597.	3.2	42
41	Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b. Leukemia, 2022, 36, 1408-1411.	3.3	37
42	Ropeginterferon alpha-2b targets JAK2V617F-positive polycythemia vera cells in vitro and in vivo. Blood Cancer Journal, 2018, 8, 94.	2.8	34
43	Interim Analysis of the Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia. Blood, 2016, 128, 479-479.	0.6	32
44	Molecular profiling and risk classification of patients with myeloproliferative neoplasms and splanchnic vein thromboses. Blood Advances, 2020, 4, 3708-3715.	2.5	31
45	MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic. Future Oncology, 2021, 17, 1449-1458.	1.1	31
46	Interlaboratory Development and Validation of a HRM Method Applied to the Detection of JAK2 Exon 12 Mutations in Polycythemia Vera Patients. PLoS ONE, 2010, 5, e8893.	1.1	27
47	Inferring the dynamics of mutated hematopoietic stem and progenitor cells induced by IFNÎ± in myeloproliferative neoplasms. Blood, 2021, 138, 2231-2243.	0.6	25
48	Mutations in exon 12 of JAK2 are mainly found in JAK2 V617Fâ€negative polycythaemia vera patients. British Journal of Haematology, 2008, 142, 676-679.	1.2	24
49	Final Results from PROUD-PV a Randomized Controlled Phase 3 Trial Comparing Ropeginterferon Alfa-2b to Hydroxyurea in Polycythemia Vera Patients. Blood, 2016, 128, 475-475.	0.6	24
50	Efficacy and safety of ruxolitinib after and versus interferon use in the RESPONSE studies. Annals of Hematology, 2018, 97, 617-627.	0.8	23
51	Impact of NFE2 mutations on AML transformation andÂoverall survival in patients with myeloproliferative neoplasms. Blood, 2021, 138, 2142-2148.	0.6	23
52	JAK2V617F myeloproliferative neoplasm eradication by a novel interferon/arsenic therapy involves PML. Journal of Experimental Medicine, 2021, 218, .	4.2	22
53	Transient expansion of TP53 mutated clones in polycythemia vera patients treated with idasanutlin. Blood Advances, 2020, 4, 5735-5744.	2.5	21
54	Treatment with Imetelstat Improves Myelofibrosis-Related Symptoms and Other Patient-Reported Outcomes in Patients with Relapsed or Refractory Higher-Risk Myelofibrosis. Blood, 2020, 136, 45-46.	0.6	21

#	Article	IF	Citations
55	Efficacy and tolerability of Janus kinase inhibitors in myelofibrosis: a systematic review and network meta-analysis. Blood Cancer Journal, 2021, 11, 135.	2.8	19
56	Unmet clinical needs in the management of CALR-mutated essential thrombocythaemia: a consensus-based proposal from the European LeukemiaNet. Lancet Haematology,the, 2021, 8, e658-e665.	2.2	17
57	Favorable overall survival with imetelstat in relapsed/refractory myelofibrosis patients compared with real-world data. Annals of Hematology, 2022, 101, 139-146.	0.8	17
58	Combination therapy with ruxolitinib plus intensive treatment strategy is feasible in patients with blastâ€phase myeloproliferative neoplasms. British Journal of Haematology, 2016, 172, 628-630.	1.2	16
59	Next-generation sequencing for JAK2 mutation testing: advantages and pitfalls. Annals of Hematology, 2019, 98, 111-118.	0.8	16
60	Evidence for Superior Efficacy and Disease Modification after Three Years of Prospective Randomized Controlled Treatment of Polycythemia Vera Patients with Ropeginterferon Alfa-2b Vs. HU/BAT. Blood, 2018, 132, 579-579.	0.6	16
61	Interferon-Alpha (IFN) Therapy Discontinuation Is Feasible in Myeloproliferative Neoplasm (MPN) Patients with Complete Hematological Remission. Blood, 2020, 136, 35-36.	0.6	16
62	Phase 3 randomized trial of momelotinib (MMB) versus best available therapy (BAT) in patients with myelofibrosis (MF) previously treated with ruxolitinib (RUX).. Journal of Clinical Oncology, 2017, 35, 7001-7001.	0.8	14
63	Imetelstat in intermediate-2 or high-risk myelofibrosis refractory to JAK inhibitor: IMpactMF phase III study design. Future Oncology, 2022, 18, 2393-2402.	1.1	14
64	Leukemic transformation and second cancers in 3649 patients with high-risk essential thrombocythemia in the EXELS study. Leukemia Research, 2018, 74, 105-109.	0.4	13
65	Enhanced calreticulin expression in red cells of polycythemia vera patients harboring the JAK2^{V617F} mutation. Haematologica, 2017, 102, e241-e244.	1.7	10
66	Long-term follow-up of JAK2 exon 12 polycythemia vera: a French Intergroup of Myeloproliferative Neoplasms (FIM) study. Leukemia, 2021, 35, 871-875.	3.3	10
67	Should Transplantation Still Be Considered for Ph1-Negative Myeloproliferative Neoplasms in Transformation?. Biology of Blood and Marrow Transplantation, 2020, 26, 1160-1170.	2.0	9
68	Potential Disease-Modifying Activity of Imetelstat Demonstrated By Reduction in Cytogenetically Abnormal Clones and Mutation Burden Leads to Clinical Benefits in Relapsed/Refractory Myelofibrosis Patients. Blood, 2020, 136, 39-40.	0.6	9
69	Emerging translational science discoveries, clonal approaches, and treatment trends in chronic myeloproliferative neoplasms. Hematological Oncology, 2019, 37, 240-252.	0.8	8
70	Impact of bone marrow fibrosis grade in postâ€polycythemia vera and postâ€essential thrombocythemia myelofibrosis: A study of the MYSEC group. American Journal of Hematology, 2020, 95, E1-E3.	2.0	8
71	Pitfalls in CALR exon 9 mutation detection: A singleâ€center experience in 571 positive patients. International Journal of Laboratory Hematology, 2020, 42, 827-832.	0.7	8
72	Long-term treatment with interferon alfa for myeloproliferative neoplasms. Lancet Haematology,the, 2017, 4, e150-e151.	2.2	7

#	Article	IF	Citations
73	From leeches to interferon: should cytoreduction be prescribed for all patients with polycythemia vera?. Leukemia, 2020, 34, 2837-2839.	3.3	7
74	Ropeginterferon Alfaâ€2b: Efficacy and Safety in Different Age Groups. HemaSphere, 2020, 4, e485.	1.2	7
75	Single-cell analysis reveals selection of TP53-mutated clones after MDM2 inhibition. Blood Advances, 2022, 6, 2813-2823.	2.5	7
76	An inherited gainâ€ofâ€function risk allele in <scp>EPOR</scp> predisposes to familial <scp>JAK2^{V617F}</scp> myeloproliferative neoplasms. British Journal of Haematology, 2022, 198, 131-136.	1.2	6
77	Altered Ca2+ Homeostasis in Red Blood Cells of Polycythemia Vera Patients Following Disturbed Organelle Sorting during Terminal Erythropoiesis. Cells, 2022, 11, 49.	1.8	6
78	Safety and efficacy findings from the open-label, multicenter, phase 3b, expanded treatment protocol study of ruxolitinib for treatment of patients with polycythemia vera who are resistant/intolerant to hydroxyurea and for whom no alternative treatments are available. Leukemia and Lymphoma, 2019, 60, 3493-3502.	0.6	5
79	CCND2 mutations are infrequent events in BCR-ABL1 negative myeloproliferative neoplasm patients. Haematologica, 2021, 106, 863-864.	1.7	5
80	Benefits of molecular profiling with next-generation sequencing for the diagnosis and prognosis of myeloproliferative neoplasms in splanchnic vein thrombosis. Journal of Hepatology, 2021, 74, 251-252.	1.8	5
81	Impact on MPN Symptoms and Quality of Life of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia: Interim Analysis Results of Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial. Blood, 2016, 128, 4271-4271.	0.6	5
82	Risk factors for vascular liver diseases. Clinics and Research in Hepatology and Gastroenterology, 2020, 44, 410-419.	0.7	4
83	PPARÎ³ agonists promote the resolution of myelofibrosis in preclinical models. Journal of Clinical Investigation, 2021, 131, .	3.9	4
84	Thromboembolic Risk Reduction and High Rate of Complete Molecular Response with Long-Term Use of Ropeginterferon Alpha-2b in Polycythemia Vera: Results from a Randomized Controlled Study. Blood, 2019, 134, 553-553.	0.6	4
85	Phase 3 trial of momelotinib (MMB) vs ruxolitinib (RUX) in JAK inhibitor (JAKi) naive patients with myelofibrosis (MF).. Journal of Clinical Oncology, 2017, 35, 7000-7000.	0.8	4
86	FREEDOM: A phase 3b efficacy and safety study of fedratinib in intermediate- or high-risk myelofibrosis patients previously treated with ruxolitinib.. Journal of Clinical Oncology, 2019, 37, TPS7072-TPS7072.	0.8	4
87	SF3B1 mutations in the Driver Clone Increase the Risk of Evolution to Myelofibrosis in Patients with Myeloproliferative Neoplasms (MPN). Blood, 2020, 136, 1-1.	0.6	4
88	ABCG2 Is Overexpressed on Red Blood Cells in Ph-Negative Myeloproliferative Neoplasms and Potentiates Ruxolitinib-Induced Apoptosis. International Journal of Molecular Sciences, 2021, 22, 3530.	1.8	3
89	Revisiting Diagnostic performances of serum erythropoÃ¯etin level and JAK2 mutation for polycythemias: analysis of a cohort of 1090 patients with red cell mass measurement. British Journal of Haematology, 2022, 196, 676-680.	1.2	3
90	Myeloproliferative Neoplasms (MPN) Clonal Evolution Landscape and Its Impact on Patients' Prognosis. Blood, 2021, 138, 317-317.	0.6	3

#	Article	IF	Citations
91	The BET Inhibitor, CPI-0610, Promotes Myeloid Differentiation in Myelofibrosis Patient Bone Marrow and Peripheral CD34+ Hematopoietic Stem Cells. Blood, 2020, 136, 37-38.	0.6	2
92	Adore: A Randomized, Open-Label, Phase 1/2 Open-Platform Study Evaluating Safety and Efficacy of Novel Ruxolitinib Combinations in Patients with Myelofibrosis. Blood, 2020, 136, 52-53.	0.6	2
93	Coexistence of a myeloproliferative disorder and secondary polycythemia in the same patient. American Journal of Hematology, 2012, 87, 646-646.	2.0	1
94	Thrombocytapheresis and sequential chemotherapy for extreme symptomatic thrombocytosis secondary to myelofibrosis: a case report. Annals of Hematology, 2020, 99, 897-898.	0.8	1
95	Impact of COVID19 Pandemic on an International MPN Patient Population: Survey Results from 1560 MPN Patients. Blood, 2020, 136, 1-3.	0.6	1
96	Chronic Exposure to Cytoreductive Treatment Shapes Clonal Evolution in Myeloproliferative Neoplasms. Blood, 2021, 138, 3620-3620.	0.6	1
97	ActualitÃ©s thÃ©rapeutiques dans les nÃ©oplasies myÃ©loprolifÃ©ratives non LMC. Revue Francophone Des Laboratoires, 2017, 2017, 59-62.	0.0	0
98	Long-term efficacy and safety of ruxolitinib in polycythaemia vera â€“ Authors' reply. Lancet Haematology,the, 2020, 7, e506.	2.2	0
99	Recent Advancements in Hematology: Knowledge, Methods and Dissemination, Part 2. Hemato, 2021, 2, 79-88.	0.2	0
100	The challenge of targets and drug discovery using large-scale screening approaches in onco-hematology. Therapie, 2021, , .	0.6	0
101	Hemato-oncopharmacology: Drugs and cancer. Therapie, 2021, , .	0.6	0
102	Perspective: Pivotal translational hematology and therapeutic insights in chronic myeloid hematopoietic stem cell malignancies. Hematological Oncology, 2022, 40, 491-504.	0.8	0